The expression of PD-1 and its ligands increases in Leishmania infection and its blockade reduces the parasite burden

被引:16
|
作者
Jafarzadeh, Abdollah [1 ,2 ]
Kumar, Sunil [3 ]
Bodhale, Neelam [3 ]
Jafarzadeh, Sara [4 ]
Nemati, Maryam [2 ,5 ]
Sharifi, Iraj [6 ]
Sarkar, Arup [7 ]
Saha, Bhaskar [3 ,4 ,7 ]
机构
[1] Kerman Univ Med Sci, Sch Med, Dept Immunol, Kerman, Iran
[2] Rafsanjan Univ Med Sci, Res Inst Basic Med Sci, Mol Med Res Ctr, Rafsanjan, Iran
[3] Natl Ctr Cell Sci, Pune 411007, India
[4] Kerman Univ Med Sci, Student Res Comm, Sch Med, Kerman, Iran
[5] Kerman Univ Med Sci, Sch Para Med, Dept Haematol & Lab Sci, Kerman, Iran
[6] Kerman Univ Med Sci, Leishmaniasis Res Ctr, Kerman, Iran
[7] Trident Acad Creat Technol, Bhubaneswar, India
关键词
Leishmaniasis; Immune responses; Programmed death-1; PD-L1; PD-L2; T cell exhaustion; T-CELL EXHAUSTION; IFN-GAMMA; TGF-BETA; POSTTRANSLATIONAL MODIFICATIONS; VISCERAL LEISHMANIASIS; PROGRAMMED DEATH-1; IMMUNE-RESPONSE; DENDRITIC CELLS; RECEPTOR; CD8(+);
D O I
10.1016/j.cyto.2022.155839
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The expression of programmed cell death protein-1 (PD-1) and its ligands-PD-L1 and PD -L2-on T cells and macrophages', respectively, increases in Leishmania infection. The PD-1/PD-L1 interaction induces T cell anergy, T cell apoptosis and exhaustion, diversion of T cells toward TH2 and T-reg cells but inhibits M1 macrophage activities by suppression of nitric oxide (NO) and reactive oxygen species (ROS) production. These changes exacerbate Leishmania infection. As PD-L1-deficient, but not PD-L2-deficient, mice were protected against L. mexicana infection, differential roles have been proposed for PD-L1 and PD-L2 in mouse models of leishmaniasis. Blockade of PD-1/PD-L1 interaction in various in vitro and Leishmania-infected mouse, hamster and dog models enhanced IFN-gamma and NO production, reduced IL-10 and TGF-8 generation, promoted T cell proliferation and reduced parasite burden. Therefore, PD-1/PD-L1 blockade is being considered as a potential therapeutic strategy to restore protective immunity during leishmaniasis, particularly, in drug-resistant cases.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] PD-1 expression and its relation with histologic and clinical variables in mycosis fungoides
    Vasquez, C.
    Fumagalli, C.
    Pons, C.
    Munoz, J.
    Szafranska, J.
    Garcia Muret, P.
    Novelli, S.
    Mozos, A.
    VIRCHOWS ARCHIV, 2017, 471 : S1 - S1
  • [42] The prognostic significance of PD-1 and its ligands in non-small cell lung cancer
    Usluer, Ozan
    Gokbayrak, Ozde Elif
    Erol, Aylin
    Akta, Tekincan Cagri
    Batihan, Guntug
    Kaya, Seyda Ors
    Ucvet, Ahmet
    Aydogdu, Zekiye
    Altun, Zekiye
    Oztop, Ilhan
    Aktas, Safiye
    TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2024, 32 (01): : 84 - 92
  • [43] Expression Pattern of Immune Checkpoints PD-1 and PD-L1 in Retinoblastoma and ITS Prognostic Significance
    Singh, L.
    Kashyap, S.
    Sen, S.
    Rizvi, M. A.
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S278 - S278
  • [44] Prognostic Value of Complement System in NSCLC and its Association with PD-1 and PD-L1 Expression
    Ajona, D.
    Pajares, M. J.
    Freire, J.
    Gomez-Roman, J.
    Martinez-Terroba, E.
    Ortiz-Espinosa, S.
    Lledo, A.
    Arenas-Lazaro, E.
    Agorreta, J.
    Lecanda, F.
    Montuenga, L.
    Pio, R.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S394 - S394
  • [45] Relevance of host and tumor PD-L1 expression in PD-L1 and PD-1 blockade
    Lin, Heng
    Wei, Shuang
    Vatan, Linda
    Kryczek, Ilona
    Zou, Weiping
    JOURNAL OF IMMUNOLOGY, 2017, 198 (01):
  • [46] PD-1 gene polymorphisms and thyroid expression of PD-1 ligands differ between Graves' and Hashimoto's diseases
    Kawabata, Mayumi
    Inoue, Naoya
    Watanabe, Mikio
    Kobayashi, Ayaka
    Hidaka, Yoh
    Miyauchi, Akira
    Iwatani, Yoshinori
    AUTOIMMUNITY, 2021, 54 (07) : 450 - 459
  • [47] Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC
    Lin, Weimin
    Chen, Miao
    Hong, Le
    Zhao, Hang
    Chen, Qianming
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [48] The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma
    Yusuke Shinchi
    Shiho Ishizuka
    Yoshihiro Komohara
    Eri Matsubara
    Remi Mito
    Cheng Pan
    Daiki Yoshii
    Kimihiro Yonemitsu
    Yukio Fujiwara
    Koei Ikeda
    Koji Tamada
    Takuro Sakagami
    Makoto Suzuki
    Cancer Immunology, Immunotherapy, 2022, 71 : 2645 - 2661
  • [49] The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
    Shogo Kumagai
    Yosuke Togashi
    Takahiro Kamada
    Eri Sugiyama
    Hitomi Nishinakamura
    Yoshiko Takeuchi
    Kochin Vitaly
    Kota Itahashi
    Yuka Maeda
    Shigeyuki Matsui
    Takuma Shibahara
    Yasuho Yamashita
    Takuma Irie
    Ayaka Tsuge
    Shota Fukuoka
    Akihito Kawazoe
    Hibiki Udagawa
    Keisuke Kirita
    Keiju Aokage
    Genichiro Ishii
    Takeshi Kuwata
    Kenta Nakama
    Masahito Kawazu
    Toshihide Ueno
    Naoya Yamazaki
    Koichi Goto
    Masahiro Tsuboi
    Hiroyuki Mano
    Toshihiko Doi
    Kohei Shitara
    Hiroyoshi Nishikawa
    Nature Immunology, 2020, 21 : 1346 - 1358
  • [50] The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma
    Shinchi, Yusuke
    Ishizuka, Shiho
    Komohara, Yoshihiro
    Matsubara, Eri
    Mito, Remi
    Pan, Cheng
    Yoshii, Daiki
    Yonemitsu, Kimihiro
    Fujiwara, Yukio
    Ikeda, Koei
    Tamada, Koji
    Sakagami, Takuro
    Suzuki, Makoto
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (11) : 2645 - 2661